Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 989

1.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.

Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.

Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15.

PMID:
24633805
2.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
3.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
4.

CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.

Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.

Neurosci Lett. 2008 Aug 1;440(2):145-9. doi: 10.1016/j.neulet.2008.05.076. Epub 2008 May 24.

PMID:
18555606
5.

Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.

Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, von Ahsen N, Krasnianski A, Armstrong VW, Zerr I.

J Alzheimers Dis. 2011;23(4):717-26. doi: 10.3233/JAD-2010-101527.

PMID:
21157024
6.

APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis.

Fukumoto H, Ingelsson M, Gårevik N, Wahlund LO, Nukina N, Yaguchi Y, Shibata M, Hyman BT, Rebeck GW, Irizarry MC.

Exp Neurol. 2003 Sep;183(1):249-53.

PMID:
12957508
7.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative.

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

8.

CSF Apo-E levels associate with cognitive decline and MRI changes.

Toledo JB, Da X, Weiner MW, Wolk DA, Xie SX, Arnold SE, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol. 2014 May;127(5):621-32. doi: 10.1007/s00401-013-1236-0. Epub 2014 Jan 3.

9.

CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.

Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM.

J Alzheimers Dis. 2009;16(3):601-7. doi: 10.3233/JAD-2009-0999.

PMID:
19276554
10.

APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.

Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ.

BMC Neurol. 2015 Apr 1;15:51. doi: 10.1186/s12883-015-0298-0.

11.

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.

Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.

Dement Geriatr Cogn Disord. 2009;27(5):458-64. doi: 10.1159/000216841. Epub 2009 May 7.

PMID:
19420940
12.

Peripheral apoE isoform levels in cognitively normal APOE ε3/ε4 individuals are associated with regional gray matter volume and cerebral glucose metabolism.

Nielsen HM, Chen K, Lee W, Chen Y, Bauer RJ 3rd, Reiman E, Caselli R, Bu G.

Alzheimers Res Ther. 2017 Jan 30;9(1):5. doi: 10.1186/s13195-016-0231-9.

13.

Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.

Huey ED, Mirza N, Putnam KT, Soares H, Csako G, Levy JA, Copenhaver B, Cohen RM, Sunderland T.

Dement Geriatr Cogn Disord. 2006;22(1):48-53. Epub 2006 May 8.

PMID:
16682793
14.

The screening of Alzheimer's patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials.

Dumurgier J, Laplanche JL, Mouton-Liger F, Lapalus P, Indart S, Prévot M, Peoc'h K, Hugon J, Paquet C.

J Neurol. 2014 Jun;261(6):1187-95. doi: 10.1007/s00415-014-7335-6. Epub 2014 Apr 12.

PMID:
24728335
15.

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.

Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA.

Ann Neurol. 2010 Jan;67(1):122-31. doi: 10.1002/ana.21843.

16.

The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease.

Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS.

Alzheimers Res Ther. 2016 Jun 30;8:25. doi: 10.1186/s13195-016-0194-x.

17.

Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.

Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM.

JAMA Neurol. 2014 Jul 1;71(7):855-62. doi: 10.1001/jamaneurol.2014.754.

PMID:
24818585
18.

Apolipoprotein E levels in the cerebrospinal fluid of north Indian patients with Alzheimer's disease.

Kandimalla RJ, Wani WY, Anand R, Kaushal A, Prabhakar S, Grover VK, Bharadwaj N, Jain K, Gill KD.

Am J Alzheimers Dis Other Demen. 2013 May;28(3):258-62. doi: 10.1177/1533317513481097.

PMID:
23612909
19.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
20.

Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.

Popp J, Lewczuk P, Frommann I, Kölsch H, Kornhuber J, Maier W, Jessen F.

J Alzheimers Dis. 2010;22(2):459-68. doi: 10.3233/JAD-2010-100561.

PMID:
21084733

Supplemental Content

Support Center